[1] 李杰, 李霞.鲍曼不动杆菌鉴定及临床分布特征[J].中华医学检验杂志, 1998, 21(2):109. [2] 熊薇, 张文池.鲍曼不动杆菌的耐药性[J].中国感染与化疗杂志, 2001, 1(2):96-97. [3] Mandell GL, Bennett JE, Dolin R, et al.Principles and practice of infectious diseases[M].5th Edition.Pennsylvania:Churchill Livingstone, 2000:2339-2344. [4] 陈平, 刘丁, 陈伟.鲍曼不动杆菌医院感染调查[J].中国现代医学志, 2003, 13(4):60-61. [5] 李景云, 马越, 陈鸿波, 等.1997-2001 年不动杆菌属临床分离株分布特点和耐药性分析[J].中国临床药理学杂志, 2002, 18(6):421-424. [6] Go ES, Urban C, Buras J, et al.Clinical and epidemiology of acinetobacter infection sensitive only to polymyxin B and sulbatum[J].Lancet, 1994, 344(8933):1329-1332. [7] Afcal-shah M, Lirermore DM.Worldwide emergency of carbapenem-resistant Acinetobacter spp[J].J Antimicrob Chemother, 1998, 41:576-577. [8] Kallel H, Hergafi L, BahloulM, et al.Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia:a matched case-control study[J].Intensive Care Med, 2007, 33(7):1162-1167. [9] 李然, 王睿.粘菌素的临床应用新进展及其不良反应[J].药物不良反应杂志, 2008, 10(4):264-270. [10] 常静侠, 蔡少华.多粘菌素与多药耐药革兰氏阴性菌感染[J].中国药物喧用与监测, 2007, 4(2):8-10. [11] Kwa A, Kasiakou SK, Tam VH, et al.Polymyxin B:similarities to and differences from colistin(polymyxin E)[J]. Expert Rev Anti Infect Ther, 2007, 5(5):811-821. |